dr. demetri on larotrectinib in trk-fusion gi cancers
Published 6 years ago • 601 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
5:20
trk inhibitor in gi cancers: adverse effect profile
-
1:35
dr. drilon on activity of larotrectinib in trk fusion–positive nsclc
-
3:20
approaching treatment for trk fusion–positive cancers
-
4:36
trk inhibition: personal experience with larotrectinib
-
0:22
copy of dr. drilon on activity of larotrectinib in trk fusion–positive nsclc
-
1:17
dr. demetri calls for nominations for the 2019 giants of cancer care
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
2:53
other approaches to trk-fusion cancers
-
1:23
dr. george demetri discusses regorafenib for patients with gist trial results
-
0:52
the impact of trk inhibitor loxo-101 (larotrectinib) on patients with trk fusion cancers
-
1:20
updated data with larotrectinib in trk fusion-positive solid tumors
-
5:08
larotrectinib for ntrk fusions: patient selection
-
1:21
dr. george demetri explains the side effects associated with regorafenib
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
1:49
dr. george demetri describes the mechanism of action of regorafenib in gist
-
2:33
advocating for early ngs testing to identify trk fusion
-
0:52
dr. van tilburg on larotrectinib in trk pediatric cancers
-
0:54
efficacy results for loxo-101 in trk fusion cancers
-
4:44
acquired resistance in trk fusion-positive cancers